HOW CAN THERE BE A SINGLE PARKINSON'S PATIENT LEFT ON THIS PLANET WHO HAS NOT YET WATCHED THIS WONDERFUL VIDEO?
Help me correct that, please.
As I promised you last year, this year, 2020, is going to be a very big year for the "Parkinson's revolution".
I invite all patient associations to show this video to all patients, on the Internet and at the association´s premises.
Hope is the best medicine.
We are going to do everything possible (and the impossible) to stop this real tragedy from happening: that these roads of hope remain unknown, buried beneath thousands of trivialities and smoke, which are part of the maze of the Parkinson's world.
Dr. David Perlmutter is a renowned neurologist who focused on the use of intravenous glutathione (through bags like those of serum) years ago. Although he later participated in a study that found no such mobility benefits (Hauser 2009), today we know a possible explanation for this apparent contradiction. The same as supplementing patients with vitamin E without giving them fat is useless because it is not assimilated (it is a fat-soluble vitamin), likewise large amounts of glutathione intravenously or parenterally require high doses of vitamins B6, B9 and B12 to be properly assimilated and even not interfere with levodopa-carbidopa (Lewis 2002).
Perlmutter's patients followed a strong treatment of vitamins and other nutrients. This I have to confirm and look for other studies, etc.
But for now it is worthwhile as a possible explanation.
In addition, recently a study with NAC (N-acetyl-cysteine), a precursor of glutathione, injected and oral raised glutathione and the amount of dopamine transporters (DAT, from 3.4 to 8.3 %), improving mobility significantly (Monti 2019).
Of course, prudence is also an important medicine. Don't forget to always consult your neurologist.
-----
"Glutathione is one of the most potent antioxidants and, in its intravenous (IV) form, the most dramatic result I have ever seen in some Parkinson's patients. Neurologist David Perlmutter is perhaps the best known physician who provides such therapy. The videos available on the Internet are invaluable in bringing hope to patients and their families. A study involving Dr. Perlmutter in 2009 shows less dramatic results for intravenous glutathione therapy (Hauser 2009).
A study entitled "Parkinson's Disease: A Disorder Due to Glutathione Deficiency in the Substance Nigra? (Perry 1982). It appears that Parkinson's patients have very low levels of glutathione in the brain (Arakawa 2007) and that this would be related to the severity of the symptoms (Sechi 1996). Sian (1994) found only 40% glutathione in the substantia nigra of Parkinson's patients. In advanced stages of the disease, the level of reduced (active) glutathione may be as low as 2% of normal (Adams 1991).
Hardly anyone questions the importance of glutathione in Parkinson's disease. The debate is over how to effectively administer it to raise the concentration in the neurons to normal levels.
By administering sustained release vitamins B6, B9, and B12, it would be possible for glutathione and vitamin B6 to be given without interfering with levodopa (Lewis 2002). Researchers have proposed precursors such as N-acetyl-cysteine or NAC (Schapira 1990, Martinez 1999, Shahripour 2014), which cross the blood-brain barrier more easily, or substances that restore the level of glutathione within cells (alpha-lipoic acid, milk thistle silymarin, melatonin, turmeric, vitamin C). The neuroprotective ability of the drug selegiline is due to the fact that it raises glutathione somewhat (Tanaka 2002)".
No comments:
Post a Comment